Reason for request
Inclusion on the lists of medicines reimbursed by National Health Insurance and approved for hospital use.
Clinical Benefit
| Substantial |
The actual benefit of this proprietary drug is substantial. |
Clinical Added Value
| no clinical added value |
The Transparency Committee considers that 3rd generation VARNOLINE CONTINU does not provide an improvement in actual benefit (IAB V) compared to 2nd generation oral contraceptives. |
eNq1mF1v2jAUhu/5FVHuSUg/Bp0C1cbaDalVGS3atBtkkkMxc+302KZ0v34OoRpMjtoafBnbec+Jz+vHR0nPVw8sWAJKKng3TKJWGADPRE75fTcc3102O+F5r5EuyJJsLWtHrSg5CoOMESm7YTkbTYFwGf28vvoC5n3AsNcIUjFdQKZ21mlFWfSNyPk1Kco1QboUNA8eQM1F3g0LrdajQSoVmix6TwJ/y4JkkMabke3ZxeRkezyNS7E3qGoJeEX4vVUUuJNmphGBqz5RcC/wuSbfYydtKkcghcYMhkTNhyiWNIfcGmJGmASnILOn/BZwyUCVQazi8SJ7kE7iZEFWI3gc2JP+ZGb7aqWarWbSbp+etM46J2etVtspFG5tlb0K5iPibNJJ2sfHSQw8XhLkglEOzUxwRbl2LNJQoCLMU3mo7O86zFMchMdXbZBTWTDyHC1k4bpVBImZBjQc8Pch5RfcoSETM3v2nz7XjMXvzHq84YanjEss9YXmqgYflyPXjegbX8OqvqJuxFOrjRcpyMPJ/hHcTvuhnjKaubLN0EeDVOPRoB5tXqjwmUgYoz8s/KA8F0/y8LjZLq+n7Is1Ma2iBebJ5Ois8yE5PXU+Tb+Ml2runAuNooDYgIjKffgy4DOxL1mMPe1SL+Y8vC/XLZDICIOaJqjpSBtjyJeezZvl/R2nasIq+vXiztUn3zXg8+360SpN8+5Lhd1I7APvxpS1eb/f4tVJ99Ida7QTZK5UIT/G8ZzIpiRmh6IZ+sP81hXrr0H3co9XfU2FSk+pT6s78O1lcj1pr93y+3aum/c3HbI1hkINe9ShgrI3dA4uDk/jf22rt7SHO/jwF2bdYhJFBffV8eipVXEv/puy8ks0bLiZzWjNv5JaW6Zx9Z+m10jj8h9Nr/EXA+Hwgw==
X8sPJgHV8ZCzwnr4
